Navigation Links
Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
Date:8/8/2012

In particular, none of the cardiovascular measures fell outside the ideal range, with no statistically significant difference between naloxone and placebo.  

For those patients with a BMI>35 (regarded to be severely obese) the results were particularly impressive, with these patients reducing their bingeing by 210.8 minutes per week compared to 83.8 minutes per week for the placebo-treated subjects at the last week of the trial,  (p=0.004). This 75.2% reduction in bingeing was achieved without patients receiving any dietary advice or psychotherapy. In fact, patients were instructed to continue eating as they would normally. This contrasts with other treatments that aim to reduce overeating - these require the patient adopt a modified diet.

Dr. Arya Sharma, Chair in Obesity Research and Management at the University of Alberta and internationally acclaimed obesity thought leader, notes, "By any measure, these are impressive results. Binge eating is a very common problem in my practice, particularly in my patients with severe obesity. These patients generally require extensive psychological interventions to control their eating behavior - a treatment that is not readily available to most patients with this disorder. The notion that bingeing can be significantly reduced with the simple application of a nasal spray would represent a major advance in the treatment of this common cause of obesity."

"These final results of the Phase II trial further confirm that our naloxone nasal spray is a very promising therapy for Binge Eating Disorder," said Dr. Roger Crystal, Chief Executive Officer of Lightlake. "We believe that the patients taking our naloxone nasal spray would have benefitted even more from this treatment if they were to continue taking it for longer. We also find it exciting that naloxone seems to work best on patients who are severely obese."

It also was observed that for those patients taking naloxone, the BMI decr
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
2. Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team
3. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
4. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
5. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
6. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
7. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
8. Juventas Therapeutics Raises $22.2 Million Series B Financing
9. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
10. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
11. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 24, 2013 Die Übersetzungen wurden ... Bei der englischen Version handelt es ... % der Teilnehmer einer groß angelegten Asthmaumfrage halten ihren ... GINA [*] -Definition [1] als kontrolliert gelten können ... generell einer von vier Denkweisen zugeordnet werden können, die ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Can economic ... from work motivate members of the public to increase ... including Johns Hopkins Carey Business School Assistant ... yes. Pointing to a large body of recent research ... the May 24, 2013, issue of Science that the ...
(Date:5/23/2013)... -- Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., a ... and therapeutics, announced today that StemCyte has become an ... car driven by James Jakes . ... 2013 season.   StemCyte, Inc. and Rahal Letterman ... umbilical cord blood banking and its educational initiative ,Stars ...
(Date:5/23/2013)... , May 23, 2013  Saddleback Memorial Medical ... recently became the first hospital on the West Coast ... This new surgical option provides women with a state-of-the-art, ... Marc Winter , M.D., a highly ... surgeon and medical director of minimally invasive surgery at ...
Breaking Biology Technology:Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3
... Array of Healthcare Products to ... Deficiency and Bleeding Disorders, OTTAWA, April 3, ... Canadian Blood Services, and Hema-Quebec, have each awarded,the ... Humate(R) P (Antihemophilic factor / von Willebrand Factor,Complex ...
... April 3 A majority of the Israeli,scientists, in ... special methods that could "put them into a creative ... as desired." Sponsored by the,Jerusalem-based Project Mind Foundation and ... when the issue of risk was raised,one fifth of ...
... CEO Honors the Anniversary by Ringing The Closing Bell(R) at ... ... 3, 2008 Edwards,Lifesciences Corporation (NYSE: EW ), a world ... its,50th anniversary of partnering with clinicians to develop life-saving,innovations. To celebrate ...
Cached Biology Technology:CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 2CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 3CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 4CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 5CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 6CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 7CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 8Project Mind Survey of Israeli Ph.D. Scientists Favors a New Standard of Creativity in Science 2Project Mind Survey of Israeli Ph.D. Scientists Favors a New Standard of Creativity in Science 3Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 2Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 3
(Date:5/23/2013)... Bochum,s medics have succeeded in treating cerebral palsy with ... brain damage, a 2.5 year old boy had been ... of survival. Just two months after treatment with the ... over the following months, the child learned to speak ... those from a Korean study, dispel the long-held doubts ...
(Date:5/22/2013)... YORK CITY, May 22, 2013 U.S. Forest Service ... team that, with funding from the TKF Foundation, will ... help communities and individuals recover from tragedy. , The ... one of six projects selected for grant funding. In ... and sacred spaces in recovery and resiliency, the 3-year, ...
(Date:5/22/2013)... Md. (May 22, 2013)The omega 3 fatty acids in ... cardiovascular diseaseso much so that the American Heart Association ... a week, particularly fatty varieties rich in omega 3s. ... a mystery. In a new study, scientists led by ... on this phenomenon by providing evidence that fish oil ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2Fish oil may help the heart beat mental stress 2
... FL, December 28, 2010 Scientists from the Florida campus ... between a structural hepatitis C virus protein (HCV) and a ... a novel method of inhibiting the production of the virus ... development. The study was published in the January ...
... based at the Lucio Lascaray building in the lava/Araba campus ... known for overseeing the SGIker DNA Bank, not only undertaking ... bank and making good use of it for their own ... BIOMICs has numerous research specialists in diverse areas of genetics ...
... Las Vegas, NV (Dec. 24, 2010) - Three ... an induced heart attack returned microRNA activity close to ... of microRNA,s studied, just six were attributed to exerting ... animal heart study four microRNA optimally regulated by ...
Cached Biology News:Scripps Research scientists identify key interaction in hepatitis C virus 2BIOMICs Group analyzes Basque diaspora DNA 2BIOMICs Group analyzes Basque diaspora DNA 3Longevinex exerts greater influence over genes than resveratrol 2Longevinex exerts greater influence over genes than resveratrol 3